

ASX ANNOUNCEMENT

19 August 2020

Respiri Executes Product Referral Agreement with APA for wheezo™

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management, is pleased to announce the execution of a definitive Product Referral Agreement (PRA) with the Australian Patients Association (APA). APA is an independent charity dedicated to supporting patients and championing and protecting the rights and interest of all Australian patients and are connected with 1,100,000 Australian patients and 15,000 Health Care Practitioners. Asthma afflicts approximately 11% of Australians.

This Agreement follows the 12 August 2020 announcement of a partnership between Respiri and the APA to support patients living with asthma through Respiri’s wheezo™ Experiential Program, a real-world asthma management study designed to support patients living with asthma.

Under the terms of the PRA, the APA has been appointed by Respiri on a non-exclusive basis to provide patient referrals to Respiri, harnessing the APA customer network, database and referral codes once wheezo™ is launched in October. In exchange for referrals directly attributable to APA, Respiri will pay APA a small commission on device sales

The PRA has an initial term of three years, with an additional three years upon contract renewal.

Mr Marjan Mikel, CEO & Managing Director of Respiri said “We are delighted to have extended our productive relationship with the APA beyond our patient Experiential Program to a commercial agreement that seeks to educate and build awareness of the benefits of wheezo™ to APA’s extensive patient network within Australia, which we believe will ultimately benefit patients in the management of their asthma with real-time measurements of wheeze delivered in a manner that allows clinicians to make informed decisions on asthma management and suitable interventions for their patients outside of the traditional clinical setting.”

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
 CEO & Managing Director
 Respiri Limited
 P: +61 408 462 873
 E: marjan@respiri.co

Mr Nicholas Smedley
 Executive Chairman
 Respiri Limited
 P: +61 447 074 160
 E: nicholas@respiri.co

This ASX announcement dated 19 August 2020 has been authorised for release by the Board of Directors of Respiri Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device records wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

™ wheezo is a trademark of Respi Limited

About the Australian Patients Association (APA)

The APA is an independent charity dedicated to supporting patients and championing and protecting the rights and interest of all Australian patients. Improving overall patient care and achieving better patient health. The APA is the VOICE of patients in Australia and was established to represent patients' interests, promote patient issues, and improve patients' outcomes. We believe that an effective patient support group, working on behalf of patients can have a proactive influence upon and effect positive change to patient care throughout Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.